Kymera Therapeutics (NASDAQ:KYMR) Receives “Outperform” Rating from Leerink Partners

Leerink Partners restated their outperform rating on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report published on Friday,Benzinga reports. The firm currently has a $60.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on KYMR. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. UBS Group lowered their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Oppenheimer upped their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, September 27th. Truist Financial reaffirmed a “buy” rating and set a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Finally, Stephens initiated coverage on shares of Kymera Therapeutics in a report on Monday, November 18th. They issued an “overweight” rating and a $65.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $53.88.

Kymera Therapeutics Stock Performance

KYMR opened at $40.11 on Friday. The firm has a market cap of $2.60 billion, a P/E ratio of -17.14 and a beta of 2.16. The business has a 50 day moving average price of $45.44 and a 200 day moving average price of $43.41. Kymera Therapeutics has a twelve month low of $22.35 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same period in the previous year, the company earned ($0.90) earnings per share. Kymera Therapeutics’s revenue for the quarter was down 20.9% on a year-over-year basis. As a group, analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of KYMR. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Kymera Therapeutics by 8.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after buying an additional 915 shares in the last quarter. Values First Advisors Inc. bought a new stake in Kymera Therapeutics during the third quarter worth about $61,000. Arizona State Retirement System increased its holdings in shares of Kymera Therapeutics by 15.6% during the second quarter. Arizona State Retirement System now owns 12,830 shares of the company’s stock worth $383,000 after buying an additional 1,730 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in shares of Kymera Therapeutics by 12.3% in the third quarter. Handelsbanken Fonder AB now owns 17,300 shares of the company’s stock valued at $819,000 after acquiring an additional 1,900 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.